English | 繁體

Search in the results

UM

Browse/Search Results:  1-10 of 65 Help

Selected(0)Clear Items/Page:    Sort:
Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma Journal article
Zou, Huimin, Lai, Yunfeng, Chen, Xianwen, Ung, Carolina Oi Lam, Hu, Hao. Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma[J]. Therapeutic Advances in Gastroenterology, 2025, 18, 1-13.
Authors:  Zou, Huimin;  Lai, Yunfeng;  Chen, Xianwen;  Ung, Carolina Oi Lam;  Hu, Hao
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:3.9/4.0 | Submit date：2025/01/22
Camrelizumab  Cost-effectiveness Analysis  Hepatocellular Carcinoma  Partitioned Survival Model  Rivoceranib  
Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma Journal article
Yao, Yawen, Hu, Yue, Meng, Xinwang, Feng, Fenyan, Xu, Feng, Wang, Guangji, Yu, Hua, Li, Juan. Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma[J]. Pharmaceutical Science Advances, 2024, 2, 100046.
Authors:  Yao, Yawen;  Hu, Yue;  Meng, Xinwang;  Feng, Fenyan;  Xu, Feng; et al.
Favorite | TC[Scopus]:1 | Submit date：2024/12/05
Sorafenib  Docetaxel  Dual-targeting Liposomes  Combination Therapy  Advanced Hepatocellular Carcinoma  
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024 Journal article
Lau, George, Obi, Shuntaro, Zhou, Jian, Tateishi, Ryosuke, Qin, Shukui, Zhao, Haitao, Otsuka, Motoyuki, Ogasawara, Sadahisa, George, Jacob, Chow, Pierce K.H., Cai, Jianqiang, Shiina, Shuichiro, Kato, Naoya, Yokosuka, Osamu, Oura, Kyoko, Yau, Thomas, Chan, Stephen L., Kuang, Ming, Ueno, Yoshiyuki, Chen, Minshan, Cheng, Ann Lii, Cheng, Gregory, Chuang, Wan Long, Baatarkhuu, Oidov, Bi, Feng, Dan, Yock Young, Gani, Rino A., Tanaka, Atsushi, Jafri, Wasim, Jia, Ji Dong, Kao, Jia Horng, Hasegawa, Kiyoshi, Lau, Patrick, Lee, Jeong Min, Liang, Jun, Liu, Zhenwen, Lu, Yinying, Pan, Hongming, Payawal, Diana A., Rahman, Salimur, Seong, Jinsil, Shen, Feng, Shiha, Gamal, Song, Tianqiang, Sun, Hui Chuan, Masaki, Tsutomu, Sirachainan, Ekaphop, Wei, Lai, Yang, Jin Mo, Sallano, Jose D., Zhang, Yanqiao, Tanwandee, Tawesak, Dokmeci, AKadir, Zheng, Shu Sen, fan, Jia, Fan, Sheung Tat, Sarin, Shiv Kumar, Omata, Masao. APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024[J]. Hepatology International, 2024, 18(6), 1661-1683.
Authors:  Lau, George;  Obi, Shuntaro;  Zhou, Jian;  Tateishi, Ryosuke;  Qin, Shukui; et al.
Favorite | TC[WOS]:1 TC[Scopus]:2  IF:5.9/6.6 | Submit date：2024/12/05
Hepatocellular Carcinoma  Systemic Therapy  Guidelines  The Asian Pacific Association For The Study Of The Liver  
Exploring the anti-hepatocellular carcinoma effects of Xianglian Pill: Integrating network pharmacology and RNA sequencing via in silico and in vitro studies Journal article
Huang, Jihan, Shi, Ruipeng, Chen, Feiyu, Tan, Hor Yue, Zheng, Jinbin, Wang, Ning, Li, Ran, Wang, Yulin, Yang, Tao, Feng, Yibin, Zhong, Zhangfeng. Exploring the anti-hepatocellular carcinoma effects of Xianglian Pill: Integrating network pharmacology and RNA sequencing via in silico and in vitro studies[J]. Phytomedicine, 2024, 133, 155905.
Authors:  Huang, Jihan;  Shi, Ruipeng;  Chen, Feiyu;  Tan, Hor Yue;  Zheng, Jinbin; et al.
Favorite | TC[WOS]:1 TC[Scopus]:1  IF:6.7/6.2 | Submit date：2024/09/03
Xianglian Pill  Hepatocellular Carcinoma  Network Pharmacology  Rna Sequencing  Big Data  
Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors Journal article
Zou, Huimin, Ge, Ying, Chen, Wenge, Yao, Dongning, Oi Lam Ung, Carolina, Lai, Yunfeng, Hu, Hao. Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors[J]. International Immunopharmacology, 2024, 132, 111947.
Authors:  Zou, Huimin;  Ge, Ying;  Chen, Wenge;  Yao, Dongning;  Oi Lam Ung, Carolina; et al.
Favorite | TC[WOS]:0 TC[Scopus]:1  IF:4.8/5.0 | Submit date：2024/05/16
Hepatocellular Carcinoma  Programmed Cell Death Protein-1 Inhibitor  Tislelizumab  Camrelizumab  China  
Rhein-based Pickering emulsion for hepatocellular carcinoma: Shaping the metabolic signaling and immunoactivation in transarterial chemoembolization Journal article
Liang, Xiaoliu, Liu, Hui, Chen, Hu, Peng, Xuqi, Li, Zhenjie, Teng, Minglei, Peng, Yisheng, Li, Jiwei, Ding, Linyu, Mao, Jingsong, Chu, Chengchao, Cheng, Hongwei, Liu, Gang. Rhein-based Pickering emulsion for hepatocellular carcinoma: Shaping the metabolic signaling and immunoactivation in transarterial chemoembolization[J]. Aggregate, 2024, e552.
Authors:  Liang, Xiaoliu;  Liu, Hui;  Chen, Hu;  Peng, Xuqi;  Li, Zhenjie; et al.
Favorite | TC[WOS]:14 TC[Scopus]:16 | Submit date：2024/05/16
Glycolysis  Hepatocellular Carcinoma  Immunoembolization  Pickering Emulsion  Transarterial Chemoembolization  
Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma Journal article
Zhang, Qi Yi, Ding, Wen, Mo, Jian Shan, Ou-yang, Shu Min, Lin, Zi You, Peng, Ke Ren, Liu, Guo Pin, Lu, Jin Jian, Yue, Pei Bin, Lei, Jin Ping, Wang, Yan Dong, Zhang, Xiao Lei. Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma[J]. ACTA PHARMACOLOGICA SINICA, 2024.
Authors:  Zhang, Qi Yi;  Ding, Wen;  Mo, Jian Shan;  Ou-yang, Shu Min;  Lin, Zi You; et al.
Favorite | TC[WOS]:6 TC[Scopus]:7  IF:6.9/7.6 | Submit date：2024/05/16
Acquired Sorafenib-resistance  Antisense Oligonucleotide  Hepatocellular Carcinoma  Stat3  
A glycyrrhetinic acid-iridium(III) conjugate as a theranostic NIR probe for hepatocellular carcinoma with mitochondrial-targeting ability Journal article
Wang, Ling, Wang, Xueliang, Chen, Feng, Song, Ying Qi, Nao, Sang Cuo, Chan, Daniel Shiu Hin, Wong, Chun Yuen, Wang, Wanhe, Leung, Chung Hang. A glycyrrhetinic acid-iridium(III) conjugate as a theranostic NIR probe for hepatocellular carcinoma with mitochondrial-targeting ability[J]. European Journal of Medicinal Chemistry, 2024, 264, 115995.
Authors:  Wang, Ling;  Wang, Xueliang;  Chen, Feng;  Song, Ying Qi;  Nao, Sang Cuo; et al.
Favorite | TC[WOS]:4 TC[Scopus]:4  IF:6.0/6.1 | Submit date：2024/02/22
Glycyrrhetinic Acid (Ga)  Hepatocellular Carcinoma  Iridium(Iii) Complex  Mitochondrial Targeting  Nir Imaging  Theranostic  
Combination strategies for first-line treatment of patients with unresectable hepatocellular carcinoma: prospect of natural products Other
2024-01-01
Authors:  ZHANG, Lele;  LU, Jinjian
Favorite | TC[WOS]:8 TC[Scopus]:7 | Submit date：2024/02/22
Combination Strategies  Immunotherapy  Natural Products  Pd-1/pd-l1  Unresectable Hepatocellular Carcinoma  
Clinical research advances in chimeric antigen receptor T - cell therapy for primary liver cancer 嵌合抗原受体 T 细胞治疗原发性肝癌临床研究进展 Journal article
Li,Shuang, Liu,Zherui, Lu,Yinying. Clinical research advances in chimeric antigen receptor T - cell therapy for primary liver cancer 嵌合抗原受体 T 细胞治疗原发性肝癌临床研究进展[J]. Journal of Clinical Hepatology, 2023, 39(5), 1019-1029.
Authors:  Li,Shuang;  Liu,Zherui;  Lu,Yinying
Favorite | TC[Scopus]:0 | Submit date：2023/08/03
Carcinoma, Hepatocellular  Chimeric Antigen  Receptors  T-lymphocytes  Therapeutics